{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T18:33:42Z","timestamp":1786473222906,"version":"build-2736575974"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T00:00:00Z","timestamp":1694476800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>Systemic juvenile idiopathic arthritis (sJIA) is a complex, systemic inflammatory disorder driven by both innate and adaptive immunity. Improved understanding of sJIA pathophysiology has led to recent therapeutic advances including a growing evidence base for the earlier use of IL-1 or IL-6 blockade as first-line treatment. We conducted a retrospective case notes review of patients diagnosed with sJIA over a 16-year period (October 2005\u2013October 2021) at Great Ormond Street Hospital for Children. We describe the clinical presentation, therapeutic interventions, complications, and remission rates at different timepoints over the disease course. We examined our data, which spanned a period of changing therapeutic landscape, to try and identify potential therapeutic signals in patients who received biologic treatment early in the disease course compared to those who did not. A total of 76-children (female <jats:italic>n<\/jats:italic>\u2009=\u200940, 53%) were diagnosed with sJIA, median age 4.5 years (range 0.6\u201314.1); 36% (27\/76) presented with suspected or confirmed macrophage activation syndrome. A biologic disease-modifying anti-rheumatic drug (bDMARD) alone was commenced as first-line treatment in 28% (<jats:italic>n<\/jats:italic>\u2009=\u200921\/76) of the cohort; however, at last review, 84% (<jats:italic>n<\/jats:italic>\u2009=\u200964\/76) had received treatment with a bDMARD. Clinically inactive disease (CID) was achieved by 88% (<jats:italic>n<\/jats:italic>\u2009=\u200967\/76) of the cohort at last review; however, only 32% (24\/76) achieved treatment-free CID. At 1-year follow-up, CID was achieved in a significantly greater proportion of children who received treatment with a bDMARD within 3\u2005months of diagnosis compared to those who did not (90% vs. 53%, <jats:italic>p<\/jats:italic>\u2009=\u20090.002). Based on an ever-increasing evidence base for the earlier use of bDMARD in sJIA and our experience of the largest UK single-centre case series described to date, we now propose a new therapeutic pathway for children diagnosed with sJIA in the UK based on early use of bDMARDs. Reappraisal of the current National Health Service commissioning pathway for sJIA is now urgently required.<\/jats:p>","DOI":"10.3389\/fped.2023.1218312","type":"journal-article","created":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T04:38:07Z","timestamp":1694579887000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Systemic juvenile idiopathic arthritis: The Great Ormond Street Hospital experience (2005\u20132021)"],"prefix":"10.3389","volume":"11","author":[{"given":"C. M.","family":"Foley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"McKenna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Gallagher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"McLellan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Alkhdher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Lacassagne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Moraitis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Papadopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Pilkington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Al Obaidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Eleftheriou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Brogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,9,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1177\/095952879708000106","article-title":"On a form of chronic joint disease in children","volume":"80","author":"Still","year":"1897","journal-title":"Med Chir Trans"},{"key":"B2","first-page":"390","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton 2001","volume":"31","author":"Petty","year":"2004","journal-title":"J Rheumatol"},{"key":"B3","first-page":"150","article-title":"Systemic juvenile idiopathic arthritis versus adult-onset Still\u2019s disease: the pertinence of changing the current classification criteria","volume":"45","author":"Silva","year":"2020","journal-title":"Acta Reum Port"},{"key":"B4","doi-asserted-by":"publisher","first-page":"15785","DOI":"10.1073\/pnas.1521837113","article-title":"Autoinflammation and autoimmunity in systemic juvenile idiopathic arthritis","volume":"112","author":"Nigrovic","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1186\/1546-0096-13-S1-O75","article-title":"HLA-DRB1*11 and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis","volume":"13","author":"Ombrello","year":"2015","journal-title":"Pediatr Rheumatol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1002\/art.38615","article-title":"Review: is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis?","volume":"66","author":"Nigrovic","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s00393-020-00779-2","article-title":"Still\u2019s disease as biphasic disorder: current knowledge on pathogenesis and novel treatment approaches","volume":"79","author":"F\u00f6ll","year":"2020","journal-title":"Z Rheumatol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1002\/art.30128","article-title":"Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series","volume":"63","author":"Nigrovic","year":"2011","journal-title":"Arthritis Rheum"},{"key":"B9","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.rdc.2021.06.003","article-title":"Pathogenesis and treatment of refractory disease courses in systemic juvenile idiopathic arthritis. Refractory arthritis, recurrent macrophage activation syndrome and chronic lung disease","volume":"47","author":"Erkens","year":"2021","journal-title":"Rheum Dis Clin N Am"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","article-title":"Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis","volume":"367","author":"De Benedetti","year":"2012","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1136\/ard.2010.134254","article-title":"A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)","volume":"70","author":"Quartier","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1056\/NEJMoa1205099","article-title":"Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis","volume":"367","author":"Ruperto","year":"2012","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1084\/jem.20050473","article-title":"Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade","volume":"201","author":"Pascual","year":"2005","journal-title":"J Exp Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3389\/fmed.2021.665028","article-title":"Short-term outcomes and predictors of effectiveness of tocilizumab in systemic juvenile idiopathic arthritis: a prospective cohort study","volume":"8","author":"Nada","year":"2021","journal-title":"Front Med"},{"key":"B15","year":"2015"},{"key":"B16","year":"2021"},{"key":"B17","year":"2011"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1002\/1529-0131(200008)43:8%3C1849::AID-ANR22%3E3.0.CO;2-F","article-title":"Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis","volume":"43","author":"Woo","year":"2000","journal-title":"Arthritis Rheum"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.3899\/jrheum.111549","article-title":"Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still\u2019s disease. An open, randomized, multicenter study","volume":"39","author":"Nordstr\u00f6m","year":"2012","journal-title":"J Rheumatol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1080\/14712598.2019.1590334","article-title":"Tocilizumab for the treatment of adult-onset Still\u2019s disease","volume":"19","author":"Castaneda","year":"2019","journal-title":"Expert Opin Biol Ther"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1080\/14712598.2019.1652591","article-title":"Biologics for the treatment of adult-onset Still\u2019s disease","volume":"19","author":"Yoo","year":"2019","journal-title":"Expert Opin Biol Ther"},{"key":"B22","year":""},{"key":"B23","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop","volume":"140","author":"Jabs","year":"2022","journal-title":"Am J Ophthalmol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"416","DOI":"10.3899\/jrheum.180331","article-title":"Predictors of effectiveness of anakinra in systemic juvenile idiopathic arthritis","volume":"46","author":"Saccomanno","year":"2019","journal-title":"J Rheumatol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1002\/acr.20497","article-title":"American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis","volume":"63","author":"Wallace","year":"2011","journal-title":"Arthritis Care Res"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1002\/art.38296","article-title":"Effectiveness of first line treatment with recombinant IL-1 receptor antagonist in steroid naive patients with new onset systemic juvenile idiopathic arthritis","volume":"66","author":"Vastert","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1002\/art.39332","article-title":"2016 classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European League Against Rheumatism\/American College of Rheumatology\/Paediatric Rheumatology International Trials Organisation collaborative initiative","volume":"68","author":"Ravelli","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.3390\/diagnostics12123095","article-title":"Lung involvement in systemic juvenile idiopathic arthritis: a narrative review","volume":"12","author":"Petrongari","year":"2022","journal-title":"Diagnostics"},{"key":"B29","year":""},{"key":"B30","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1136\/annrheumdis-2020-eular.3169","article-title":"Emapalumab (anti-interferon-gamma monoclonal antibody) in patients with macrophage activation syndrome (MAS) complicating systemic juvenile idiopathic arthritis (SJIA)\u2014scientific abstract","volume":"180","author":"De Benedetti","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B31","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1136\/ard-2022-223739","article-title":"Efficacy and safety of emapalumab in macrophage activation syndrome","volume":"8","author":"De Benedetti","year":"2023","journal-title":"Ann Rheum Dis Press"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1002\/art.40099","article-title":"Proinflammatory cytokine environments can drive interleukin-17 overexpression by \u03b3\/\u03b4 T cells in systemic juvenile idiopathic arthritis","volume":"69","author":"Kessel","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1172\/jci.insight.132508","article-title":"Th17 reprogramming of T cells in systemic juvenile idiopathic arthritis","volume":"5","author":"Henderson","year":"2020","journal-title":"JCI Insight"},{"key":"B34","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s12969-022-00768-6","article-title":"First-line options for systemic juvenile idiopathic arthritis treatment: an observational study of childhood arthritis and rheumatology research alliance consensus treatment plans","volume":"20","author":"Beukelman","year":"2022","journal-title":"Pediatr Rheumatol Online J"},{"key":"B35","first-page":"1","article-title":"Clinical commissioning policy proposition: anakinra\/tocilizumab for the treatment adult onset still\u2019s disease refractory to secondline therapy (adults)","year":"2018","journal-title":"NHS Engl Policy"},{"key":"B36","first-page":"1133","article-title":"Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis","volume":"34","author":"Behrens","year":"2007","journal-title":"J Rheumatol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"3160","DOI":"10.1002\/art.38802","article-title":"Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients","volume":"66","author":"Minoia","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMoa1911326","article-title":"Emapalumab in children with primary hemophagocytic lymphohistiocytosis","volume":"382","author":"Locatelli","year":"2020","journal-title":"N Engl J Med"},{"key":"B39","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1097\/00062752-199704060-00005","article-title":"Hemopoietic blood and marrow transplants in the treatment of severe autoimmune disease","volume":"4","author":"Tyndall","year":"1997","journal-title":"Curr Opin Hematol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1038\/sj.bmt.1703686","article-title":"Clinically demonstrable anti-autoimmunity mediated by allogeneic immune cells favorably affects outcome after stem cell transplantation in human autoimmune diseases","volume":"30","author":"Hinterberger","year":"2002","journal-title":"Bone Marrow Transpl"},{"key":"B41","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1182\/bloodadvances.2017014449","article-title":"Allogeneic hematopoietic stem cell transplantation for severe, refractory juvenile idiopathic arthritis","volume":"2","author":"Silva","year":"2018","journal-title":"Blood Adv"},{"key":"B42","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1097\/BOR.0000000000000823","article-title":"Haematopoietic stem cell transplantation in paediatric rheumatic disease","volume":"33","author":"Abinun","year":"2021","journal-title":"Curr Opin Rheumatol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1002\/acr.21889","article-title":"Pulmonary hypertension and other potentially fatal pulmonary complications in systemic juvenile idiopathic arthritis","volume":"65","author":"Kimura","year":"2013","journal-title":"Arthritis Care Res"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1002\/art.41073","article-title":"Systemic juvenile idiopathic arthritis-associated lung disease: characterization and risk factors","volume":"71","author":"Schulert","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1093\/rheumatology\/keab673","article-title":"Interfering with interferons: targeting the JAK-STAT pathway in complications of systemic juvenile idiopathic arthritis (SJIA)","volume":"61","author":"Verweyen","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"B46","doi-asserted-by":"publisher","first-page":"3263","DOI":"10.1007\/s10067-018-4297-6","article-title":"Impact of biologics on disease course in systemic onset juvenile idiopathic arthritis","volume":"37","author":"Baris","year":"2018","journal-title":"Clin Rheumatol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1002\/art.42037","article-title":"2021 American College of Rheumatology guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for oligoarthritis, temporomandibular joint arthritis, and systemic juvenile idiopathic arthritis","volume":"74","author":"Onel","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1002\/art.40865","article-title":"Treatment to target using recombinant interleukin-1 receptor antagonist as first-line monotherapy in new-onset systemic juvenile idiopathic arthritis: results from a five-year follow-up study","volume":"71","author":"Ter Haar","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1002\/art.41612","article-title":"Early treatment and IL1RN single-nucleotide polymorphisms affect response to anakinra in systemic juvenile idiopathic arthritis","volume":"73","author":"Pardeo","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1186\/s13075-017-1462-2","article-title":"Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry","volume":"19","author":"Horneff","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1134312","DOI":"10.3389\/fped.2023.1134312","article-title":"JAK inhibitors in systemic juvenile idiopathic arthritis","volume":"11","author":"He","year":"2023","journal-title":"Front Pediatr"},{"key":"B52","author":"Leek","year":""}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2023.1218312\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T04:38:13Z","timestamp":1694579893000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2023.1218312\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,12]]},"references-count":52,"alternative-id":["10.3389\/fped.2023.1218312"],"URL":"https:\/\/doi.org\/10.3389\/fped.2023.1218312","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,12]]},"article-number":"1218312"}}